Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Apr, 27 2026
Sep, 1 2025
Sep, 21 2025
Jul, 7 2025
Feb, 28 2025